secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001493152-23-008693
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity Q4/FY2022 net loss $11.6M/$40.4M; cash runway extended through 2025 after $100M PIPE
--------------------------------------------------------------------------------

- Net loss Q4 2022 $11.6M ($0.69/sh); full year net loss $40.4M ($2.64/sh).
- Dosed first patient in Phase 3 VIKTORIA-1 trial, triggering $100M PIPE closing and $20M term loan drawdown.
- Cash runway expected through 2025; combined with debt facility and existing cash.
- Updated Phase 1b data at SABCS: median PFS 42.3 months in treatment-naive advanced breast cancer.
- Enrollment ongoing in FACT-1/2 for CELsignia; interim results expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/0001493152-23-008693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315223008693/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer